APA (7th ed.) Citation

Rugo, H. S., Bardia, A., Marmé, F., Cortés, J., Schmid, P., Loirat, D., . . . Tolaney, S. M. (2023). Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): A randomised, open-label, multicentre, phase 3 trial. The lancet, 402(10411), . https://doi.org/10.1016/S0140-6736(23)01245-X

Chicago Style (17th ed.) Citation

Rugo, Hope S., et al. "Overall Survival with Sacituzumab Govitecan in Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer (TROPiCS-02): A Randomised, Open-label, Multicentre, Phase 3 Trial." The Lancet 402, no. 10411 (2023). https://doi.org/10.1016/S0140-6736(23)01245-X.

MLA (9th ed.) Citation

Rugo, Hope S., et al. "Overall Survival with Sacituzumab Govitecan in Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer (TROPiCS-02): A Randomised, Open-label, Multicentre, Phase 3 Trial." The Lancet, vol. 402, no. 10411, 2023, https://doi.org/10.1016/S0140-6736(23)01245-X.